Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of EVER4010001 with pembrolizumab in advanced solid tumors
CTR20200590Phase 2Suspended
- Sponsor
- EverNov Medicines
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roblitinib, pembrolizumab in Nonhematologic neoplasms, sponsored by EverNov Medicines. Started Aug 2020; status: suspended.
02
Drugs
roblitinibpembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200590.